Small Cap Gainers: Atara Biotherapeutics, Inc. (NASDAQ:ATRA), BioTime, Inc. (NYSEMKT:BTX), AAC Holdings, Inc. (NYSE:AAC), eLong Inc. (NASDAQ:LONG), Aratana Therapeutics, Inc. (NASDAQ:PETX)

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) belongs to Healthcare sector. Its weekly performance is 17.82%. On last trading day company shares ended up $53.41. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) distance from 50-day simple moving average (SMA50) is 20.20%. Atara Biotherapeutics, Inc. (NASDAQ:ATRA), announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $125.0 million. In addition, Atara Bio expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares in the offering will be sold by Atara Bio.

BioTime, Inc. (NYSEMKT:BTX) shares increased 7.37% in last trading session and ended the day at $3.64. BTX Gross Margin is 81.50% and its return on assets is -70.10%. BioTime, Inc. (NYSEMKT:BTX) quarterly performance is -31.32%. On June 30, 2015, BioTime, Inc. (NYSEMKT:BTX) subsidiary OncoCyte Corporation (“OncoCyte”) entered into an Agreement with two of its shareholders (the “Investors”) who purchased shares of OncoCyte common stock in a rights offering that was completed on May 8, 2015. Under the Agreement, the Investors have agreed that if on or before June 30, 2016 OncoCyte conducts another rights offering to its shareholders at a pre-offer valuation of at least $40,000,000, the Investors will purchase shares in that offering with an aggregate purchase price equal to the lesser of (a) a percentage of total amount of capital which OncoCyte then seeks to raise in the rights offer and in any concurrent offering to third parties equal to the Investors’ aggregate pro rata share of the outstanding OncoCyte common stock on the record date for the rights offering, determined on a fully diluted basis, and (b) $3,000,000.00, or such lesser amount requested by OncoCyte.

On 09 July, AAC Holdings, Inc. (NYSE:AAC) shares increased 6.68% and was closed at $43.61. AAC Holdings, Inc. (NYSE:AAC) year to date (YTD) performance is 41.04%. On 2 July, AAC Holdings, Inc. (NYSE: AAC), has acquired Referral Solutions Group, LLC and Taj Media, LLC for $35 million in cash and $25 million in stock through its operating subsidiary, American Addiction Centers, Inc., a national leader in addiction treatment and rehabilitation, and its indirect subsidiary, Sober Media Group, LLC, officials announced today.

eLong Inc. (NASDAQ:LONG) ended the last trading day at $15.05. Company weekly volatility is calculated as 8.77% and price to cash ratio as 1.96. eLong Inc. (NASDAQ:LONG) showed a weekly performance of -10.74%. eLong, Inc. (NASDAQ:LONG) announced the appointment of Mr. Hao Jiang as its Chief Executive Officer, effective July 8, 2015. eLong also announced that Mr. Guangfu Cui, its former Chief Executive Officer, will continue to provide services to the Company as a consultant.

Aratana Therapeutics, Inc. (NASDAQ:PETX) shares increased 5.23% in last trading session and ended the day at $15.29. PETX Gross Margin is 28.60% and its return on assets is -19.00%. Aratana Therapeutics, Inc. (NASDAQ:PETX) quarterly performance is -5.09%. On 26 June, Aratana Therapeutics, Inc. (NASDAQ:PETX), announced positive results from its pivotal field effectiveness study of capromorelin (AT-002), the company’s innovative therapeutic for appetite stimulation in dogs.

Leave a Reply

Your email address will not be published. Required fields are marked *